Available Forms: Tablets
Available Strengths: 5 mg, 10 mg
Reference Brands: Maxalt (USA)
Category: Neurology
Quick Response Guaranteed | Verified Suppliers
Product Description:
Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist used for the acute treatment of migraine attacks with or without aura. It works by constricting dilated cranial blood vessels and inhibiting the release of inflammatory neuropeptides involved in migraine pathophysiology. Rizatriptan provides effective relief from migraine pain as well as associated symptoms such as nausea, vomiting, and sensitivity to light and sound. It is administered orally and is available as conventional tablets and orally disintegrating tablets that dissolve on the tongue, offering faster onset and ease of use. Rizatriptan is intended for use during an active migraine attack and is not indicated for migraine prevention.
Rizatriptan is used for the acute treatment of migraine attacks with or without aura in adults. It helps relieve migraine symptoms such as headache, nausea, vomiting, and sensitivity to light or sound once the migraine has started, but it is not used to prevent migraines.
Rizatriptan is made from the active pharmaceutical ingredient rizatriptan benzoate, a synthetic compound belonging to the triptan class of medications. It acts as a selective serotonin (5-HT1B/1D) receptor agonist.
The most well-known trade names of rizatriptan are Maxalt and Maxalt-MLT.
The original brand Maxalt was developed and marketed by Merck & Co., Inc. Many generic versions are now manufactured by multiple pharmaceutical companies worldwide.
The complete generic name is rizatriptan benzoate.
Brand names include Maxalt and Maxalt-MLT.
Rizatriptan is manufactured globally, including in the USA, Europe, and India, by both innovator and WHO-GMP/FDA-approved generic pharmaceutical manufacturers.
Strength: 125 mg/mL, 200 mg, 250 mg, 300 mg, 500 mg, 100 mg/mL
Form: Tablet / Capsule/ Injection / Oral syrup
Reference Brands: Depakene (USA), Depakine (EU/LATAM), Valprol (India)
Strength: 50 mg, 100 mg
Form: Tablets
Reference Brands: Ubrelvy (USA/India)
Strength: 100 mg
Reference Brands: Tasmar (USA/EU)
Strength: 50 mg ,100 mg
Reference Brands: Xadago (USA/EU)
By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under ‘Fair use.’
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Stay updated on pharma trends and marketplace opportunities.
Online · B2B Pharma · Medical Tourism · NPP